Boston Scientific (NYSE:BSX) Reaches New 12-Month Low - Here's What Happened

Key Points

• Boston Scientific shares fell to a new 52-week low, trading as low as $51.46 after closing at $57.64 the previous day, amid heavy volume of nearly 7.0 million shares.
• Despite the drop, analysts remain broadly positive: the stock carries a Moderate Buy consensus rating with an average price target of $92.71, though several firms recently trimmed their targets.
• The company recently reported solid quarterly results with earnings and revenue slightly ahead of estimates, and its board approved a $5 billion share repurchase program while insiders also bought stock.

Shares of Boston Scientific Corporation (NYSE:BSX - Get Free Report) reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $51.46 and last traded at $50.8310, with a volume of 6969715 shares trading hands. The stock had previously closed at $57.64.

Wall Street Analyst Weigh In

BSX has been the topic of several analyst reports. Evercore reduced their price objective on shares of Boston Scientific from $112.00 to $96.00 and set an "outperform" rating on the stock in a research note on Thursday, February 5th. Jefferies Financial Group reduced their price target on Boston Scientific from $110.00 to $100.00 and set a "buy" rating on the stock in a research report on Wednesday, April 22nd. Stifel Nicolaus decreased their price target on Boston Scientific from $90.00 to $85.00 and set a "buy" rating for the company in a research note on Tuesday, April 21st. The Goldman Sachs Group lowered their price objective on Boston Scientific from $87.00 to $84.00 and set a "buy" rating for the company in a research report on Wednesday, April 22nd. Finally, Oppenheimer set a $90.00 price objective on Boston Scientific in a research note on Thursday, April 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $92.71.

Boston Scientific Stock Performance

The stock has a fifty day simple moving average of $61.52 and a two-hundred day simple moving average of $79.54. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The stock has a market capitalization of $77.31 billion, a price-to-earnings ratio of 21.77, a P/E/G ratio of 1.06 and a beta of 0.62.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm's revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Analysts forecast that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has approved a stock repurchase program on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company's leadership believes its stock is undervalued.

Insider Activity

In related news, Director Cheryl Pegus purchased 1,770 shares of the firm's stock in a transaction on Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the purchase, the director owned 1,770 shares in the company, valued at approximately $99,987.30. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David C. Habiger acquired 2,250 shares of the business's stock in a transaction dated Wednesday, May 20th. The shares were bought at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the transaction, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. This represents a 19.35% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 9,800 shares of company stock worth $554,012 in the last quarter. 0.34% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Murphy & Mullick Capital Management Corp lifted its holdings in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 170 shares in the last quarter. FWL Investment Management LLC bought a new stake in Boston Scientific during the 2nd quarter valued at $26,000. Swiss RE Ltd. bought a new stake in Boston Scientific during the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC acquired a new position in Boston Scientific during the fourth quarter worth $26,000. Finally, United Community Bank lifted its stake in shares of Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock valued at $27,000 after buying an additional 147 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.